Amendment: EMA pharmacovigilance fee inflation adjustment

This procedure updates the fees charged by the European Medicines Agency (EMA) for monitoring the safety of medicines. The adjustment is based on inflation, ensuring the fees cover the actual costs of pharmacovigilance activities.

This affects pharmaceutical companies that pay these fees. It ensures the EMA has adequate resources to protect public health by overseeing the safety of medicines available on the market.